BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy in First-Line Advanced Non-Squamous Non-Small Cell Lung Cancer in China

    NEXT STORY
    Roche’s IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone met one of its co-primary endpoints
    PREV STORY
    CB2 Insights Announces Record Annual Revenue of $13.4 million for FY 2019 Sequential Growth of 25%
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    The American Health Council Appoints Nicholas Avitabile, MD to Board of Physicians

    NEW YORK, Aug. 17, 2018 (GLOBE NEWSWIRE) -- The American Health Council appointed Nicholas ...

    author_avatar
    NASDAQ Market News

    Immunicum AB (publ) Delårsrapport för första kvartalet (januari-mars 2020)

    author_avatar
    NASDAQ Market News

    Novartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk

    Study showed a significant 15% reduction of major adverse cardiovascular events (MACE) in people ...

    author_avatar
    NASDAQ Market News